Alnylam Pharmaceuticals Inc. (ALNY)

86.50
1.90 2.25
NASDAQ : Health Technology
Prev Close 84.60
Open 84.90
Day Low/High 84.77 / 87.19
52 Wk Low/High 60.27 / 96.14
Volume 1.28M
Avg Volume 697.90K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 9.51B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Alnylam Pharmaceuticals, Inc.

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results For Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyria

Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results For Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented updated results from the ongoing Phase 1/2 open-label extension (OLE) study of givosiran, an investigational RNAi therapeutic,...

Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2018 and reviewed recent commercial and R&D highlights.

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 10:15 am...

Microsoft, Ross Stores, Pitney Bowes: 'Mad Money' Lightning Round

Microsoft, Ross Stores, Pitney Bowes: 'Mad Money' Lightning Round

Jim Cramer takes a look at Microsoft, Ross Stores, Pitney Bowes, Alnylam Pharmaceuticals, Golar LNG, ResMed and more.

Market Whiplash: Cramer's 'Mad Money' Recap (Friday 11/2/18)

Market Whiplash: Cramer's 'Mad Money' Recap (Friday 11/2/18)

Jim Cramer breaks down the day's roller-coaster action amid confusing news. Plus, he's got your game plan for next week.

Alnylam To Webcast Conference Call Discussing Third Quarter 2018 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2018 on Wednesday, November 7, 2018, before the U.

Alnylam Expands Alnylam Act® Program To Improve Diagnosis Of Primary Hyperoxaluria Type 1 (PH1) And Aligns With FDA On Trial Design For ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran

Alnylam Expands Alnylam Act® Program To Improve Diagnosis Of Primary Hyperoxaluria Type 1 (PH1) And Aligns With FDA On Trial Design For ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has expanded the Alnylam Act ® program to include no-charge, third-party genetic testing and counseling for adults and children who may have...

Alnylam Announces Advocacy For Impact Grants To Inspire Unique Solutions That Address Unmet Needs Affecting The Rare Disease Community

Alnylam Announces Advocacy For Impact Grants To Inspire Unique Solutions That Address Unmet Needs Affecting The Rare Disease Community

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Advocacy for Impact Grants, a global competitive grants program that aims to inspire patient advocacy groups to develop solutions to address...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc.

Alnylam Announces Plan To Initiate Rolling Submission Of A New Drug Application And Pursue Full Approval For Givosiran

Alnylam Announces Plan To Initiate Rolling Submission Of A New Drug Application And Pursue Full Approval For Givosiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.

Alnylam Appoints Dr. Margaret Hamburg To Board Of Directors

Alnylam Appoints Dr. Margaret Hamburg To Board Of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment of Dr.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc.

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting...

Alnylam Submits Clinical Trial Authorization (CTA) Application For ALN-AAT02, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Submits Clinical Trial Authorization (CTA) Application For ALN-AAT02, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted an Clinical Trial Authorization (CTA) application to the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a...

Alnylam Launches ONPATTRO™ (patisiran), The First-Ever RNAi Therapeutic, In Germany

Alnylam Launches ONPATTRO™ (patisiran), The First-Ever RNAi Therapeutic, In Germany

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that ONPATTRO (patisiran) is now available in Germany.

Alnylam Reports New Platform Innovations For RNAi Therapeutics At The Oligonucleotide Therapeutics Society 2018 Annual Meeting

Alnylam Reports New Platform Innovations For RNAi Therapeutics At The Oligonucleotide Therapeutics Society 2018 Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular...

Alnylam Announces Submission Of New Drug Application In Japan For ONPATTRO™ (patisiran Sodium) For Treatment Of Hereditary ATTR Amyloidosis

Alnylam Announces Submission Of New Drug Application In Japan For ONPATTRO™ (patisiran Sodium) For Treatment Of Hereditary ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the...

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Alnylam Pharmaceuticals, Inc. Investors (ALNY)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Alnylam Pharmaceuticals, Inc. Investors (ALNY)

Law Offices of Howard G. Smith announces an investigation on behalf of Alnylam Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc.

Alnylam Announces Positive Topline Results From Interim Analysis Of ENVISION Phase 3 Study Of Givosiran In Patients With Acute Hepatic Porphyria

Alnylam Announces Positive Topline Results From Interim Analysis Of ENVISION Phase 3 Study Of Givosiran In Patients With Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting...

Alnylam To Webcast Presentation At The 2018 Cantor Global Healthcare Conference

Alnylam To Webcast Presentation At The 2018 Cantor Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:45 am ET at the...

Alnylam Announces Publication In Circulation Of Exploratory Cardiac Endpoint Data From APOLLO Phase 3 Study Of Patisiran

Alnylam Announces Publication In Circulation Of Exploratory Cardiac Endpoint Data From APOLLO Phase 3 Study Of Patisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today publication of data from exploratory cardiac assessments in the APOLLO Phase 3 study of patisiran, an RNAi therapeutic for the treatment of the...

Alnylam Receives Approval Of ONPATTRO™ (patisiran) In Europe

Alnylam Receives Approval Of ONPATTRO™ (patisiran) In Europe

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO ™ (patisiran) for the treatment of hereditary transthyretin-mediated...

Alnylam To Webcast Presentations At Upcoming September Investor Conferences

Alnylam To Webcast Presentations At Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 2018 Wells Fargo Securities Healthcare Conference on Wednesday, September 5,...

Alnylam Completes Enrollment In ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Completes Enrollment In ENVISION Phase 3 Study Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias (AHPs)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has achieved full patient accrual in its ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid...

Alnylam Announces Alignment On Value-Based Agreements With Leading Health Insurers And Launches Comprehensive Patient Support Services For ONPATTRO™ (patisiran)

Alnylam Announces Alignment On Value-Based Agreements With Leading Health Insurers And Launches Comprehensive Patient Support Services For ONPATTRO™ (patisiran)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has agreed on the structure and key terms of value-based agreements (VBA) with leading health insurers for ONPATTRO™ (patisiran) lipid complex...

ONPATTRO™ (patisiran) Packaging And Product Vial (Photo: Business Wire)

ONPATTRO™ (patisiran) Packaging And Product Vial (Photo: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference...

Alnylam Announces That The United Kingdom's MHRA Grants Early Access To Patisiran

Alnylam Announces That The United Kingdom's MHRA Grants Early Access To Patisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted patisiran, an investigational RNAi therapeutic in development for the...